Video

Treating Relapsed and Refractory Hodgkin Lymphoma

For High-Definition, Click

The clinical management of patients with relapsed or refractory Hodgkin lymphoma is difficult. In general, the standard of care is salvage chemotherapy followed by autologous stem cell transplant, for patients who are sensitive to chemotherapy. However, if patients are not eligible for transplants the treatment decision becomes more complicated, since a myriad of options exist, Lauren C. Pinter-Brown, MD, points out.

Craig H. Moskowitz, MD, employs ifosfamide, carboplatin, and etoposide (ICE) as a first-line salvage therapy. However, he notes, other regimens are effective and the ultimate goal of treatment should be remission, regardless of the exact regimen administered.

The exact regimen to administer relies on the ultimate treatment goals and needs, Pinter-Brown suggests. In some situations, inpatient regimens, such as ICE, may be inconvenient for patients, requiring the switch to an outpatient treatment, such as gemcitabine, vinorelbine, and liposomal doxorubicin (GVD). To this point, Jonathan W. Friedberg, MD, notes that he prefers GVD as a first-line salvage therapy, since his patients generally travel long distances to receive treatment.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity